Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

The Arnold O. Beckman Postdoctoral Fellowship in Chemical Sciences or Chemical Instrumentation Award Program supports advanced research by postdoctoral scholars within the core areas of fundamental chemistry or the development and build of chemical instrumentation.

The Laura Bassi Scholarship was established by Editing Press in 2018 with the aim of providing editorial assistance to postgraduates and junior academics whose research focuses on neglected topics of study, broadly construed, within their disciplines.

The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).

The NSF ADVANCE program provides grants to enhance the systemic factors that support equity and inclusion and to mitigate the systemic factors that create inequities in the academic profession and workplaces. Systemic (or organizational) inequities may exist in areas such as policy and practice as well as in organizational culture and climate. For example, practices in academic departments that result in the inequitable allocation of service or teaching assignments may impede research productivity, delay advancement, and create a culture of differential treatment and rewards. Similarly, policies and procedures that do not mitigate implicit bias in hiring, tenure, and promotion decisions could lead to women and racial and ethnic minorities being evaluated less favorably, perpetuating historical under-participation in STEM academic careers and contributing to an academic climate that is not inclusive. All NSF ADVANCE proposals are expected to use intersectional approaches in the design of systemic change strategies in recognition that gender, race and ethnicity do not exist in isolation from each other and from other categories of social identity. The solicitation includes four funding tracks: Institutional Transformation (IT), Adaptation, Partnership, and Catalyst, in support of the NSF ADVANCE program goal to broaden the implementation of systemic strategies that promote equity for STEM faculty in academic workplaces and the academic profession.

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.

Eligible applicants are tenure-track faculty members at U.S. institutions whose primary appointment is in a department of astronomy, biochemistry, biophysics, chemistry, or physics, but not in a school of medicine or engineering. The department must grant both the BS/BA and Ph.D. For the 2013 proposal cycle, eligibility is limited to faculty members who started their first tenure-track position anytime in calendar year 2010.

This FOA invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions.  

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of innovative statistical, data science, or other quantitative approaches to studying the health effects of complex chemical mixtures in environmental epidemiology. 

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

 In this Funding Opportunity Announcement (FOA), applications are solicited for: i.) systems biology studies on regulatory and metabolic networks of microbes, microbial consortia, and microbe-plant interactions involved in biogeochemical cycling of carbon, ii.) development and application of -omics approaches to investigate microbial community functional processes involved in carbon cycling in terrestrial ecosystems.

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-16-006) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-16-007) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization.

The specific objective of the "E-Rare-3" call is to promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or have achieved a significant stage in the development process in rare indications. Projects should aim at discovering new therapeutic uses for agents whose clinical safety has already been characterized to move quickly into proof of concept trials in the selected rare diseases' patient population.

Today the Foundation funds projects in medicine, life sciences and the physical sciences. Particular areas of interest include innovative medical investigations and applications, endangered animals and ecosystems, and climate change.

This fall, OARS will host a series of brown-bag workshops on navigating the NSF proposal process.  Workshops will be held select Tuesdays from noon to 1:00pm in Pearson 208.  You are welcome to attend any or all of the sessions.  Click through for dates and registration information.

The intention of this Funding Opportunity Announcement is to improve the prevention, diagnosis, and treatment of vulvodynia.  By definition, vulvar discomfort or pain without a clear etiology is termed vulvodynia. Some organizations use the term vulvodynia to indicate vulvar pain of unknown etiology for more than 3 months.  For the purposes of this announcement, vulvodynia and vulvar pain will be used interchangeably.  The overall incidence of vulvodynia has been reported as 4.2 cases per 100 person-years in one population based study, with others estimating that persistent vulvar pain affects 9 to 18 percent of women at some point during their lifetime. Current evidence suggests that incidence rates vary by age, ethnicity and marital status.

The Office of Basic Energy Sciences (BES), U.S. Department of Energy (DOE), announces its interest in receiving applications from small groups of investigators for support of experimental and theoretical efforts to advance ultrafast chemical and materials sciences that utilize x-ray free electron lasers.

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-17-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-17-004) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.